Ekso Bionics Holdings Inc (NASDAQ:EKSO) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 546,200 shares, a decrease of 76.6% from the June 30th total of 2,330,000 shares. Based on an average daily trading volume, of 2,960,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.9% of the company’s stock are short sold.
An institutional investor recently bought a new position in Ekso Bionics stock. Strategic Wealth Designers purchased a new position in Ekso Bionics Holdings Inc (NASDAQ:EKSO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 13,550 shares of the company’s stock, valued at approximately $114,000. Strategic Wealth Designers owned 0.18% of Ekso Bionics at the end of the most recent quarter. 15.25% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on the stock. Aegis cut their price target on shares of Ekso Bionics from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, May 21st. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Ekso Bionics in a report on Friday. Finally, Zacks Investment Research cut shares of Ekso Bionics from a “buy” rating to a “hold” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Ekso Bionics presently has an average rating of “Buy” and an average target price of $9.25.
Shares of EKSO stock opened at $6.52 on Friday. Ekso Bionics has a 12-month low of $2.25 and a 12-month high of $18.15. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.53 and a current ratio of 1.86. The firm’s 50 day moving average is $6.52 and its 200 day moving average is $3.08.
Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Thursday, July 30th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($1.32). Ekso Bionics had a negative return on equity of 206.13% and a negative net margin of 156.16%. The company had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $1.85 million. On average, analysts predict that Ekso Bionics will post -1.98 earnings per share for the current year.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Featured Article: Basic Economics
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.